BIOTIE THERAPIES CORP. Press Release September 4, 2009 at 11a.m.

Biotie Therapies to present at Rodman & Renshaw Annual HealthcareConference

Rodman & Rodman Annual Global Investment Conference 2009

Live webcast will be available at www.biotie.com

Biotie Therapies Corp. (NASDAQ OMX: BTH1V) announced today that Dr.Timo Veromaa, President and Chief Executive Officer, will give anupdate on the company at the Rodman & Renshaw 11th Annual HealthcareConference in New York on Wednesday September 9, 2009 at 10:50 a.m.local time (5:50 p.m. Finnish time).

For more information on the conference:http://www.rodmanrenshaw.com/conferences?id=30

The audio and slide presentation will be webcasted live and will beavailable for 90 days at www.biotie.com.

For further information, please contact:Virve Nurmi, Biotie Therapies Corp.tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

About Biotie Therapies Corp.

Biotie is a drug discovery and development company focused on centralnervous system and inflammatory diseases. It has a broad range ofinnovative small molecule and biological drug candidates at differentstages of clinical and pre-clinical development. Biotie's productsaddress diseases with high unmet medical need and significant marketpotential, including addiction and psychotic disorders, rheumatoidarthritis, psoriasis and chronic obstructive pulmonary disease(COPD). The most advanced product, nalmefene for alcohol dependence,is currently in phase III clinical development by licensing partnerH. Lundbeck A/S.

The commercial value of the pipeline has been demonstrated throughexisting alliances with top-tier global pharmaceutical companies suchas Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finlandand Radebeul, Germany.Shares are listed on NASDAQ OMX Helsinki Ltd.

For more information, please refer to www.biotie.com

This announcement was originally distributed by Hugin. The issuer issolely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.